Trump 2.0 could see a rise in biopharmaceutical M&A deals
A change in FTC leadership would likely see a relaxation of antitrust enforcement and an increase in biopharma M&A activity.
A change in FTC leadership would likely see a relaxation of antitrust enforcement and an increase in biopharma M&A activity.
What's Your Reaction?
